Social Share:
Adamas Pharmaceuticals received FDA approval for Second Indication for GOCOVRI®, the first approved medication to treat OFF and dyskinesia motor complications in Parkinson’s patients.
Hologic and Google Cloud will collaborate to advance next-generation digital diagnostic capabilities and catalyze new discoveries in cervical cancer per their new agreement.
Jazz Pharma will acquire GW Pharma, maker of the first FDA-approved prescription cannabinoid drug, used to treat epilepsy, in a cash-and-stock deal worth $7.2B.
Gilead is partnering with Gritstone Oncology for their latest play to help develop an HIV-specific therapeutic vaccine in a $60 million upfront deal with up to $785M in options.
Horizon Therapeutics has acquired AstraZeneca spinout Viela Bio for $3B, adding a host of early-stage candidates, R&D capabilities, and an approved antibody to its pipeline.
Illumina is partnering with Sequoia Capital to launch a genomics incubator in China.
Cytiva acquired Canadian aseptic filling innovator Vanrx Pharmasystems in a play to advance personalized medicine innovation.
Encodia closed their $75M Series C Financing led by Northpond Ventures and Deerfield Management.
Salk’s NOMIS Center received $9.5M from the NOMIS foundation to continue Salk’s legacy of advancing and improving human health and immunity.
ViaCyte appointed Michael Yang as President & CEO and shared an update on their expansion of manufacturing capacity to support therapeutic research.
Merck will collaborate with Artiva in a milestone-heavy deal focused on Artiva’s CAR-NK cell manufacturing platform.
MAIA Biotechnology entered a clinical supply agreement with Regeneron to evaluate a novel administration of non-small cell lung cancer drug Libtayo®.
